Physician profile
Arshdeep Tindni
NPI 1023138401
$40,770.53
in general payments reported to CMS, 2019-2025
36 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $511 · 2021: $1,464 · 2022: $13K · 2023: $8,559 · 2024: $1,203 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Honoraria: $6,000 · Food and Beverage: $2,629 · Travel and Lodging: $1,569 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,242.00 |
| Honoraria | $6,000.00 |
| Food and Beverage | $2,629.17 |
| Travel and Lodging | $1,569.02 |
| Education | $137.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14,972.92 | 2021-2025 | |
| Akebia Therapeutics INC | $14,627.84 | 2020-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $6,240.28 | 2022-2024 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $779.43 | 2019-2024 | Breztri, Farxiga |
| Mallinckrodt Hospital Products INC. | $455.34 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $451.93 | 2019-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $384.58 | 2019-2024 | Velphoro |
| Mallinckrodt Enterprises LLC | $330.36 | 2019 | |
| Glaxosmithkline, LLC. | $307.77 | 2021-2023 | Benlysta |
| Horizon Therapeutics Plc | $273.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $265.98 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $252.79 | 2019-2023 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $223.22 | 2021-2025 | Jynarque |
| Ardelyx, INC. | $149.44 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $132.30 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $106.29 | 2022-2024 | Krystexxa |
| Aurinia Pharma U.S., INC. | $95.03 | 2021-2022 | |
| Nxstage Medical, INC. | $87.81 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.68 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $67.73 | 2021-2023 | Gattex |
| Travere Therapeutics, INC. | $61.06 | 2022-2024 | |
| Outset Medical INC | $58.57 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $51.80 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $43.38 | 2021 | |
| Alnylam Pharmaceuticals INC. | $39.62 | 2021-2022 | |
| Daiichi Sankyo INC. | $38.32 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $29.50 | 2021 | |
| Qorumpartners | $25.89 | 2022 | |
| Ani Pharmaceuticals, INC. | $21.65 | 2022 | |
| Renalytix Ai, INC. | $20.69 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Merck Sharp & Dohme LLC | $19.10 | 2025 | Prevymis |
| Bard Peripheral Vascular, INC. | $17.85 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.62 | 2025 | Empaveli |
| Novo Nordisk INC | $14.48 | 2024 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $13.89 | 2022 | |
| Cmp Pharma, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshdeep Tindni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.